Moran Wealth Management LLC Buys 74,621 Shares of Fresenius Medical Care AG (NYSE:FMS)

Moran Wealth Management LLC lifted its stake in shares of Fresenius Medical Care AG (NYSE:FMS) by 47.0% in the 3rd quarter, Holdings Channel reports. The fund owned 233,376 shares of the company’s stock after acquiring an additional 74,621 shares during the quarter. Moran Wealth Management LLC’s holdings in Fresenius Medical Care were worth $4,971,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. Wulff Hansen & CO. grew its position in Fresenius Medical Care by 1,809.0% in the second quarter. Wulff Hansen & CO. now owns 343,429 shares of the company’s stock valued at $6,556,000 after purchasing an additional 325,439 shares in the last quarter. Triasima Portfolio Management inc. grew its position in Fresenius Medical Care by 27.4% in the second quarter. Triasima Portfolio Management inc. now owns 85,430 shares of the company’s stock valued at $1,631,000 after purchasing an additional 18,360 shares in the last quarter. Crossmark Global Holdings Inc. grew its position in Fresenius Medical Care by 60.4% in the third quarter. Crossmark Global Holdings Inc. now owns 62,889 shares of the company’s stock valued at $1,340,000 after purchasing an additional 23,692 shares in the last quarter. QRG Capital Management Inc. grew its position in Fresenius Medical Care by 10.9% in the second quarter. QRG Capital Management Inc. now owns 60,309 shares of the company’s stock valued at $1,151,000 after purchasing an additional 5,946 shares in the last quarter. Finally, Creative Planning grew its position in Fresenius Medical Care by 18.9% in the second quarter. Creative Planning now owns 40,140 shares of the company’s stock valued at $766,000 after purchasing an additional 6,373 shares in the last quarter. Institutional investors own 8.25% of the company’s stock.

Fresenius Medical Care Stock Performance

Shares of FMS stock opened at $21.79 on Thursday. The stock has a market cap of $12.79 billion, a P/E ratio of 18.01, a P/E/G ratio of 1.02 and a beta of 0.91. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.37 and a quick ratio of 1.02. The company has a fifty day moving average price of $20.75 and a two-hundred day moving average price of $20.26. Fresenius Medical Care AG has a one year low of $17.93 and a one year high of $22.76.

Analysts Set New Price Targets

FMS has been the subject of a number of analyst reports. StockNews.com initiated coverage on shares of Fresenius Medical Care in a research report on Saturday, November 9th. They issued a “strong-buy” rating for the company. Truist Financial raised their target price on shares of Fresenius Medical Care from $22.00 to $23.00 and gave the company a “hold” rating in a research report on Monday, October 7th. Finally, Berenberg Bank initiated coverage on shares of Fresenius Medical Care in a research note on Wednesday, November 6th. They issued a “buy” rating and a $25.60 price target for the company. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, one has given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Fresenius Medical Care currently has a consensus rating of “Hold” and an average price target of $24.30.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.